Cargando…
Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients
To compare the efficacy of spironolactone and trichlormethiazide, as add‐on therapy to renin–angiotensin system (RAS) blockade, for reduction of albuminuria in diabetic patients with chronic kidney disease (CKD), we conducted this randomized, open‐labeled, parallel‐group, active‐controlled, per‐prot...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley-Blackwell
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015670/ https://www.ncbi.nlm.nih.gov/pubmed/24843672 http://dx.doi.org/10.1111/jdi.12029 |
_version_ | 1782315375034105856 |
---|---|
author | Hase, Michiyo Babazono, Tetsuya Ujihara, Noriko Uchigata, Yasuko |
author_facet | Hase, Michiyo Babazono, Tetsuya Ujihara, Noriko Uchigata, Yasuko |
author_sort | Hase, Michiyo |
collection | PubMed |
description | To compare the efficacy of spironolactone and trichlormethiazide, as add‐on therapy to renin–angiotensin system (RAS) blockade, for reduction of albuminuria in diabetic patients with chronic kidney disease (CKD), we conducted this randomized, open‐labeled, parallel‐group, active‐controlled, per‐protocol‐design study. Type 2 diabetic patients receiving an angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker, with persistent albuminuria (≥100 mg/g creatinine) were randomly assigned to either spironolactone (25 mg/day) or trichlormethiazide (2 mg/day). The primary outcome was the change in albuminuria at 24 weeks of treatment. In patients who completed 24 weeks of treatment with spironolactone (n = 18) and trichlormethiazide (n = 15), albuminuria decreased significantly by −57.6 ± 21.3% (SD) (P < 0.001) and −48.4 ± 27.1% (P < 0.001), respectively. There was no significant difference in the change in albuminuria between groups (P = 0.270). This pilot study suggests add‐on therapy with spironolactone or trichlormethiazide to RAS blockade may be comparably beneficial to reducing albuminuria in type 2 diabetic patients. This trial was registered with UMIN‐CTR (no. UMIN000008914). |
format | Online Article Text |
id | pubmed-4015670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Wiley-Blackwell |
record_format | MEDLINE/PubMed |
spelling | pubmed-40156702014-05-19 Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients Hase, Michiyo Babazono, Tetsuya Ujihara, Noriko Uchigata, Yasuko J Diabetes Investig Articles To compare the efficacy of spironolactone and trichlormethiazide, as add‐on therapy to renin–angiotensin system (RAS) blockade, for reduction of albuminuria in diabetic patients with chronic kidney disease (CKD), we conducted this randomized, open‐labeled, parallel‐group, active‐controlled, per‐protocol‐design study. Type 2 diabetic patients receiving an angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker, with persistent albuminuria (≥100 mg/g creatinine) were randomly assigned to either spironolactone (25 mg/day) or trichlormethiazide (2 mg/day). The primary outcome was the change in albuminuria at 24 weeks of treatment. In patients who completed 24 weeks of treatment with spironolactone (n = 18) and trichlormethiazide (n = 15), albuminuria decreased significantly by −57.6 ± 21.3% (SD) (P < 0.001) and −48.4 ± 27.1% (P < 0.001), respectively. There was no significant difference in the change in albuminuria between groups (P = 0.270). This pilot study suggests add‐on therapy with spironolactone or trichlormethiazide to RAS blockade may be comparably beneficial to reducing albuminuria in type 2 diabetic patients. This trial was registered with UMIN‐CTR (no. UMIN000008914). Wiley-Blackwell 2013-01-24 2013-05-06 /pmc/articles/PMC4015670/ /pubmed/24843672 http://dx.doi.org/10.1111/jdi.12029 Text en © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd |
spellingShingle | Articles Hase, Michiyo Babazono, Tetsuya Ujihara, Noriko Uchigata, Yasuko Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title | Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title_full | Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title_fullStr | Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title_full_unstemmed | Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title_short | Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
title_sort | comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015670/ https://www.ncbi.nlm.nih.gov/pubmed/24843672 http://dx.doi.org/10.1111/jdi.12029 |
work_keys_str_mv | AT hasemichiyo comparisonofspironolactoneandtrichlormethiazideasaddontherapytoreninangiotensinblockadeforreductionofalbuminuriaindiabeticpatients AT babazonotetsuya comparisonofspironolactoneandtrichlormethiazideasaddontherapytoreninangiotensinblockadeforreductionofalbuminuriaindiabeticpatients AT ujiharanoriko comparisonofspironolactoneandtrichlormethiazideasaddontherapytoreninangiotensinblockadeforreductionofalbuminuriaindiabeticpatients AT uchigatayasuko comparisonofspironolactoneandtrichlormethiazideasaddontherapytoreninangiotensinblockadeforreductionofalbuminuriaindiabeticpatients |